{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T18:07:29Z","timestamp":1784311649153,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.clcc.2019.02.004","type":"journal-article","created":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T23:33:06Z","timestamp":1550100786000},"page":"125-132.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR\/MET Dual Inhibition"],"prefix":"10.1016","volume":"18","author":[{"given":"Lorenza","family":"Rimassa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Bozzarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Pietrantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Cordio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7593-8138","authenticated-orcid":false,"given":"Sara","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Toppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Zaniboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Bordonaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Di Bartolomeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Tomasello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Dadduzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Tronconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Piombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annunziata","family":"Gloghini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Di Tommaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2019.02.004_bib1","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2019.02.004_bib2","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1158\/2159-8290.CD-12-0558","article-title":"Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer","volume":"3","author":"Bardelli","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clcc.2019.02.004_bib3","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1158\/1078-0432.CCR-10-0568","article-title":"HGF rescues colorectal cancer cells from EGFR inhibition via MET activation","volume":"17","author":"Liska","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2019.02.004_bib4","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1158\/0008-5472.CAN-13-2340-T","article-title":"MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors","volume":"74","author":"Luraghi","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.clcc.2019.02.004_bib5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2009.11.022","article-title":"Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC","volume":"17","author":"Turke","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clcc.2019.02.004_bib6","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1158\/1535-7163.MCT-09-1173","article-title":"ARQ197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with anti-tumor activity","volume":"9","author":"Munshi","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clcc.2019.02.004_bib7","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1200\/JCO.2010.31.0367","article-title":"Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies","volume":"29","author":"Yap","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2019.02.004_bib8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/ijc.30049","article-title":"A\u00a0randomized, placebo-controlled, phase 1\/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy","volume":"139","author":"Eng","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clcc.2019.02.004_bib9","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.4161\/cbt.26343","article-title":"Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: clinical outcome and biomarkers of efficacy","volume":"14","author":"Pietrantonio","year":"2013","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.clcc.2019.02.004_bib10","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/annonc\/mdr623","article-title":"Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?","volume":"23","author":"Santini","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2019.02.004_bib11","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1159\/000346328","article-title":"A\u00a0phase II study of high-dose cetuximab plus irinotecan in colorectal cancer patients with KRAS wild-type tumors who progressed after standard dose of cetuximab plus irinotecan","volume":"84","author":"Fora","year":"2013","journal-title":"Oncology"},{"key":"10.1016\/j.clcc.2019.02.004_bib12","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.21873\/anticanres.11063","article-title":"Efficacy and toxicity of panitumumab after progression on cetuximab and predictive value of MiR-31-5p in metastatic wild-type KRAS colorectal cancer patients","volume":"36","author":"Kiss","year":"2016","journal-title":"Anticancer Res"},{"issue":"Suppl","key":"10.1016\/j.clcc.2019.02.004_bib13","volume":"36","author":"Rossini","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2019.02.004_bib14","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1369\/0022155413503662","article-title":"Expression of asialoglycoprotein receptor 1 in human hepatocellular carcinoma","volume":"61","author":"Shi","year":"2013","journal-title":"J\u00a0Histochem Cytochem"},{"key":"10.1016\/j.clcc.2019.02.004_bib15","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1158\/1078-0432.CCR-16-1863","article-title":"Heterogeneity of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer","volume":"23","author":"Pietrantonio","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2019.02.004_bib16","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/14737159.2018.1440210","article-title":"Bright-field in situ hybridization detects gene alterations and viral infections useful for personalized management of cancer patients","volume":"18","author":"Volpi","year":"2018","journal-title":"Expert Rev Mol Diagn"},{"issue":"Suppl 4","key":"10.1016\/j.clcc.2019.02.004_bib17","article-title":"Phase II study of tivantinib (ARQ 197) in combination with cetuximab in EGFR inhibitor-resistant, MET-high, KRAS wild-type metastatic colorectal cancer","volume":"26","author":"Rimassa","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2019.02.004_bib18","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clcc.2019.02.004_bib19","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2019.02.004_bib20","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1093\/annonc\/mdx546","article-title":"Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study","volume":"28","author":"Cremolini","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2019.02.004_bib21","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1158\/2159-8290.CD-16-0297","article-title":"MET-driven resistance to dual EGFR and BRAF blockade may be overcome by switching from EGFR to MET inhibition in BRAF-mutated colorectal cancer","volume":"6","author":"Pietrantonio","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clcc.2019.02.004_bib22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3892\/ijo.2013.1941","article-title":"Dual inhibition of EGFR and c-Met kinase activation by MJ-56 reduces metastasis of HT29 human colorectal cancer cells","volume":"43","author":"Chen","year":"2013","journal-title":"Int J Oncol"},{"key":"10.1016\/j.clcc.2019.02.004_bib23","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMra1510064","article-title":"The primary outcome fails - what next?","volume":"375","author":"Pocock","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2019.02.004_bib24","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/bjc.2017.196","article-title":"Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer","volume":"117","author":"Oddo","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2019.02.004_bib25","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1158\/1078-0432.CCR-13-1321","article-title":"Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET\u2013letter","volume":"19","author":"Rimassa","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2019.02.004_bib26","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1158\/1535-7163.MCT-14-0462","article-title":"Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance","volume":"13","author":"Aoyama","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clcc.2019.02.004_bib27","doi-asserted-by":"crossref","first-page":"4364","DOI":"10.1158\/1078-0432.CCR-16-3118","article-title":"Proliferation markers are associated with MET expression in hepatocellular carcinoma and predict tivantinib sensitivity in\u00a0vitro","volume":"23","author":"Rebouissou","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2019.02.004_bib28","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/nrclinonc.2017.40","article-title":"Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges","volume":"14","author":"Bradley","year":"2017","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002818304250?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002818304250?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:05:58Z","timestamp":1761519958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002818304250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S1533002818304250"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2019.02.004","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR\/MET Dual Inhibition","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2019.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}